News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Depomed, Inc. Pockets $40 Million as Abbott Laboratories Returns Gralise Rights
March 18, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Depomed will regain from Abbott Laboratories the rights to its drug Gralise, it said Thursday, and will receive a $40 million from the company.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Abbott Laboratories
MORE ON THIS TOPIC
Layoff Tracker
Pfizer, Geron Downsize To Streamline Costs
December 12, 2025
·
95 min read
·
BioSpace Editorial Staff
Weight loss
Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech
December 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Pfizer’s Cost Cuts Claim 200+ Jobs in Switzerland: Report
December 11, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Novartis Unites With Relation in $1.7B Inflammatory Skin Disease Pact
December 9, 2025
·
2 min read
·
Tristan Manalac
